Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Dolophine, Methadose
Synonyms :
Methadone
Class :
Opioid Analgesics
Brand Name :
Dolophine, Methadose
Synonyms :
Methadone
Class :
Opioid Analgesics
Dosage Forms & StrengthsÂ
Adult Â
Injectable solution: Schedule IIÂ
10mg/mlÂ
Tablet: Schedule IIÂ
5 mgÂ
10 mgÂ
Dispersible tablet: Schedule IIÂ
40 mgÂ
Oral solution: Schedule IIÂ
5mg/5mlÂ
10mg/5mlÂ
Oral concentrate solution: Schedule IIÂ
10mg/mlÂ
Dosage Forms & StrengthsÂ
Injected solution: Schedule IIÂ
10mg/mlÂ
Tablet: Schedule IIÂ
5 mgÂ
10 mgÂ
40 mgÂ
Dispersible tablet: Schedule IIÂ
40 mgÂ
Oral solution: Schedule IIÂ
5mg/5mlÂ
10mg/5mlÂ
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
methadone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
methadone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
methadone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
methadone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
lemborexant may enhance the CNS depressant effect of CNS depressants
may enhance the serum concentration of CYP3A4 inhibitors
may increase the CNS depressant effect of CNS Depressants
may have an increased CNS depressant effect when combined with buprenorphine
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with methotrimeprazine
may have an increased CNS depressive effect when combined with oxycodone
may have an increased CNS depressant effect when combined with flunitrazepam
may have an increased CNS depressant effect when combined with CNS depressants
calcium, magnesium, potassium and sodium oxybateÂ
may have an increased CNS depressant effect when combined with oxybate salt products
suvorexant: they may increase the CNS depressant effect of CNS Depressants
may have an increased Effect of CNS depressant when combined with serotonergic opioids
Ropeginterferon Alfa-2b: they may increase the adverse effect of CNS Depressants
nitrazepam: they may increase the CNS depressant effect of CNS Depressants
tiotropium: they may increase the CNS depressant effect of CNS Depressants
oxychlorosene: they may increase the CNS depressant effect of CNS Depressants
when both drugs are combined, there may be an increased risk or severity of QTC prolongation  
QTc interval is increased both by lenvatinib and methadone
when both drugs are combined, there may be an increased QTC interval  
may increase the QT-prolonging effect and enhance the risk of bradycardia, hypokalemia
CYP3A strong enhancers of the small intestine may reduce the bioavailability of methadone
when used together, entrectinib and methadone both increase the QTc interval
when used together, encorafenib and methadone both increase the QTc interval
may increase the QTc interval when combined
may increase the CNS depressant effect
may increase the CNS depressant effect
CNS depressants increase the effect of CNS depression of thalidomide
CNS depressants increase the efficacy of cannabinoid products
CNS depressants increase the efficacy of cannabinoid products
may increase the CNS depressant effect of bromperidol
may have an increased CNS depressive effect when combined with flunarizine
it increases the effect of CNS depressants
may have an increased CNS depressant effect when combined with orphenadrine
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with paraldehyde
may increase the CNS depressant effect of flibanserin
eluxadoline: they may increase the CNS depressant effect of CNS Depressants
ipratropium: they may increase the CNS depressant effect of CNS Depressants
glycopyrrolate: they may increase the CNS depressant effect of CNS Depressants
chlorthalidone: they may increase the CNS depressant effect of CNS Depressants
chloral hydrate: they may increase the CNS depressant effect of CNS Depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may have an increased CNS depressive effect when combined with cannabinoid-containing products
may have an increased CNS depressive effect when combined with cannabinoid-containing products
methadone: they may diminish the serum concentration of CYP3A4 Inducers
methadone: they may diminish the serum concentration of CYP3A4 Inducers
methadone: they may diminish the serum concentration of CYP3A4 Inducers
methadone: they may diminish the serum concentration of CYP3A4 Inducers
methadone: they may diminish the serum concentration of CYP3A4 Inducers
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
methadone concentration serum may be enhanced by aromatase inhibitors
methadone concentration serum may be enhanced by aromatase inhibitors
methadone concentration serum may be enhanced by aromatase inhibitors
methadone concentration serum may be enhanced by aromatase inhibitors
may decrease the therapeutic effect when combined with lubiprostone
Combining methadone with pranlukast may cause a reduction in the methadone’s metabolism
may have an increased CNS depressant effect when combined with alcohol
When dexrabeprazole and methadone is used together, this leads to reduction in the dexrabeprazole’s metabolism
When encainide is used together with methadone, this leads to a reduction in the encainide’s metabolism
methadone: they may increase the CNS depressant effect of CNS Depressants
methadone: they may increase the CNS depressant effect of CNS Depressants
methadone: they may increase the CNS depressant effect of CNS Depressants
methadone: they may increase the CNS depressant effect of CNS Depressants
methadone: they may increase the CNS depressant effect of CNS Depressants
methadone leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
When methadone is used together with profenamine, this leads to enhanced risk or seriousness of adverse events
the effect of methadone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
exemestane (aromatase inhibitors) may decrease the serum concentration of methadone
Aromatase inhibitors may enhance the serum concentration of methadone
Aromatase inhibitors may enhance the serum concentration of methadone
May reduce the therapeutic efficacy of tipranavir
CNS Depressants may enhance the CNS depressant effect of brexanolone
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of sedation of ropinirole
may increase the CNS depressant effect
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may decrease the therapeutic effect of antibiotics
may have an increased CNS depressive effect when combined with brexanolone
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with Cyproheptadine
may increase the toxic effect of CNS depressants
may increase the adverse effect of CNS Depressants
doxylamine: they may increase the CNS depressant effect of CNS Depressants
perampanel: they may increase the CNS depressant effect of CNS Depressants
valerian: they may increase the CNS depressant effect of CNS Depressants
it increases the effect of CNS depressants
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
acetaminophen/doxylamine/dextromethorphanÂ
may increase the CNS depressant effect of Doxylamine
metoclopramide increases the effect of CNS depressants
The Therapeutic effectiveness of abacavir may be reduced by methadone
methadone concentration serum may be reduced by atazanavir
pramipexole: they may increase the sedative effect of CNS Depressants
mianserin: they may increase the CNS depressant effect of CNS Depressants
trimeprazine: they may increase the CNS depressant effect of CNS Depressants
piribedil: it may increase the CNS depressant effect of CNS Depressants
ceritinib: they may increase the CNS depressant effect of CNS Depressants
halofantrine: they may increase the CNS depressant effect of CNS Depressants
lomitapide: they may increase the CNS depressant effect of CNS Depressants
methadone: they may increase the CNS depressant effect of CNS Depressants
pilsiicainide hydrochloride: they may increase the CNS depressant effect of CNS Depressants
mirabegron: they may increase the CNS depressant effect of CNS Depressants
dapoxetine: they may increase the CNS depressant effect of CNS Depressants
sacubitril: they may increase the CNS depressant effect of CNS Depressants
pholcodine: they may increase the CNS depressant effect of CNS Depressants
adenosine: it may increase the risk or severity of CNS depression
ajmaline: it may increase the risk or severity of CNS depression
alprazolam: it may increase the risk or severity of CNS depression
benazepril: it may increase the risk or severity of CNS depression
bufexamac: it may increase the risk or severity of CNS depression
butabarbital: it may increase the risk or severity of CNS depression
cefaclor: it may increase the risk or severity of CNS depression
carvedilol: it may increase the risk or severity of CNS depression
alosetron: it may increase the risk or severity of CNS depression
ampicillin: it may increase the risk or severity of CNS depression
anagrelide: it may decreased the serum concentration of CNS depressants
antipyrine: it may decreased the serum concentration of CNS depressants
arbutamine: it may decreased the serum concentration of CNS depressants
binimetinib: it may increase the metabolism of CNS depressants
chlorpromazine: it may increase the metabolism of CNS depressants
aclidinium: it may increase the risk of CNS depression
baclofen: it may increase the risk of CNS depression
balsalazide: it may increase the risk of CNS depression
benorilate: it may increase the risk of CNS depression
boceprevir: it may increase the risk of CNS depression
bosentan: it may increase the risk of CNS depression
bretylium: it may increase the risk of CNS depression
brexpiprazole: it may increase the risk of CNS depression
carisoprodol: it may increase the risk of CNS depression
carprofen: it may increase the risk of CNS depression
the sedative property of hyoscine may be increased
the rate of metabolism may be altered
it decreases the level of methadone by inhibiting gastrointestinal absorption
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of oxycodone
it increases the toxicity of CNS depressants
CNS depressants increase the effect of zolpidem
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists
Action and Spectrum:Â
Methadone is an agonist at mu-opioid receptors also an antagonist at NMDA receptors in the brain and tissues. It may help analgesic effects to reduce opioid tolerance development in chronic pain.Â
Adverse reaction:Â
Frequency Not DefinedÂ
AgitationÂ
DizzinessÂ
DysphoriaÂ
EuphoriaÂ
Angina pectorisÂ
BradycardiaÂ
Cardiac arrestÂ
FaintnessÂ
Mental clouding or depressionÂ
NervousnessÂ
QT-interval prolongationÂ
Respiratory arrestÂ
RestlessnessÂ
Myocardial infarctionÂ
NauseaÂ
PruritusÂ
SedationÂ
SeizuresÂ
Severe cardiac arrhythmiasÂ
SyncopeÂ
Urinary retentionÂ
Ventricular tachycardiaÂ
Visual disturbancesÂ
WeaknessÂ
Post marketing ReportsÂ
DisorientationÂ
Congenital oculomotor disordersÂ
InsomniaÂ
ConfusionÂ
Black box warning:Â
Monitor patients for respiratory depression during treatment initiation as dose increases.Â
Contraindications/caution:Â
Contraindications:Â
HypersensitivityÂ
Respiratory DepressionÂ
Cautions:Â
Respiratory DepressionÂ
Cardiac ArrhythmiasÂ
Head InjuryÂ
HypotensionÂ
Pregnancy Warnings:Â
Pregnancy category: N/AÂ
Lactation: It is present in low levels in human breast milkÂ
Pregnancy categories:Â
Pharmacology: Methadone blocks the NMDA receptor to manage neuropathic pain and reduce opioid tolerance. It helps with chronic pain to inhibit serotonin and norepinephrine reuptake.Â
Pharmacodynamics:Â It depresses respiratory centres in the brainstem to reduce responsiveness to carbon dioxide, which can cause significant respiratory depression.Â
Pharmacokinetic:Â
Absorption:Â
It reaches peak plasma time in 1 to 7.5 hours.Â
DistributionÂ
It shows protein bound of 85 to 90%.Â
Metabolism:Â
The metabolism takes place in liver.Â
Excretion and elimination:Â
It is excreted through urine route.Â
Administration:Â
It is available in tablet and solution for oral use.Â
Patient information leaflet:Â
Generic Name: MethadoneÂ
Why do we use Methadone?Â
Methadone is indicated in pain management including chronic pain and neuropathic pain.Â
It is also used for detoxification in adults.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
